Sitagliptin Market Report 2025 (Global Edition)

Global Sitagliptin Market Report 2025 Market Size Split by Type Outlook: (Injection, Tablets), by Application Outlook: (Diabetes, Epilepsy, Others)

Sitagliptin Market Report Description

We have various report editions of Sitagliptin Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Competitive Landscape of the Sitagliptin Market

The competitive landscape of the sitagliptin market is characterized by the presence of several key players offering various formulations and combination therapies. Competition is driven by factors such as pricing strategies, product differentiation, and marketing efforts. Additionally, companies are focusing on expanding their market share through strategic partnerships, research, and development of innovative formulations. The rise of generics and alternative therapies also intensifies competition in the market.

In August 2022, Cadila Pharmaceuticals launched generic versions of sitagliptin in India under the brand names Jankey and Sitenali to treat type 2 diabetes. Sitagliptin, a DPP-4 inhibitor, is a unique drug for managing high blood glucose levels, also known as hyperglycemia. Uncontrolled blood glucose can lead to severe complications, including atherosclerosis, stroke, heart attack, retinopathy, neuropathy, and nephropathy. (Source: https://www.cadilapharma.com/news-release/cadila-pharma-launches-generic-sitagliptin-versions-to-treat-uncontrolled-type-2-diabetes/) In October 2021, Zent2U announced the successful completion of the pivotal bioequivalence study for Sitagliptin 100 mg. The study, conducted under fasting conditions, compared their Sitagliptin film-coated tablets (Zentiva) with the European reference product Januvia® (MSD), and the bioequivalence parameters were met. The product, available in 25 mg, 50 mg, and 100 mg strengths, aligned with their strategy to expand their anti-diabetes portfolio. (Source: https://www.zentiva.com/news/2021/2021-08-12-zent2u-sitagliptin-development) In January 2023, Sandoz Canada announced the launch of PrSandoz® Sitagliptin and PrSandoz® Sitagliptin-Metformin. These products were indicated as additional therapy to improve glycemic control in adult patients with type 2 diabetes mellitus, where current treatment, along with diet and exercise, failed to provide adequate control. They were also used to help reduce long-term complications of the disease and support maintaining quality of life over time. (Source: https://www.sandoz.ca/en/news/media-releases/sandoz-canada-launches-prsandoz-sitagliptin-and-prsandoz-sitagliptin-metformin/)

Top Companies Market Share in Sitagliptin Industry: (In no particular order of Rank)

• Merck & Co. Inc.
• Novartis AG
• Eli Lilly and Company
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim GmbH
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Pfizer Inc
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Sitagliptin Market

Which Region Dominates the Sitagliptin Market in 2024?

According to Cognitive Market Research, North America currently dominates the Sitagliptin market, and the region is expected to have significant growth during the projected period. The region benefits from strong support for research and development, increasing adoption of oral hypoglycemic agents, and favorable reimbursement policies, making sitagliptin a preferred choice for diabetes management.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Increasing awareness about diabetes management and rising disposable incomes are contributing factors, driving demand for effective treatments like sitagliptin, which is expected to continue expanding in the coming years.

The current report Scope analyzes Sitagliptin Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Sitagliptin

According to Cognitive Market Research, the global Sitagliptin market size was estimated at USD 6914.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 2765.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 33.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Sitagliptin market with a market size of USD 2182.22 million in 2024 and is projected to grow at a CAGR of 33.2% during the forecast period. The US holds a major share of the sitagliptin market due to high diabetes prevalence and treatment demand.
• The Canada Sitagliptin market had a market share of USD 331.90 million in 2024 and is projected to grow at a CAGR of 34.2% during the forecast period. Canada's sitagliptin market is growing due to rising diabetes prevalence and increasing focus on effective treatments.
• The Mexico Sitagliptin market is projected to witness growth at a CAGR of 33.9% during the forecast period, with a market size of USD 251.69 million in 2024.

Europe Sitagliptin

According to Cognitive Market Research, the global Sitagliptin market size was estimated at USD 6914.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 2074.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 33.7% from 2024 to 2031.

• The United Kingdom Sitagliptin market had a market share of USD 348.49 million in 2024 and is projected to grow at a CAGR of 34.5% during the forecast period. The UK is leading the sitagliptin market with advanced healthcare systems and growing diabetes awareness.
• The France Sitagliptin market is projected to witness growth at a CAGR of 32.9% during the forecast period, with a market size of USD 190.84 million in 2024.
• According to Cognitive Market Research, the German Sitagliptin market size was valued at USD 410.72 million in 2024 and is projected to grow at a CAGR of 33.9% during the forecast period. Advanced healthcare systems and increasing demand for diabetes treatment support Germany's sitagliptin market growth.
• The Italy Sitagliptin market is projected to witness growth at a CAGR of 33.1% during the forecast period, with a market size of USD 178.39 million in 2024.
• The Russia Sitagliptin market is projected to witness growth at a CAGR of 32.7% during the forecast period, with a market size of USD 321.52 million in 2024.
• The Spain Sitagliptin market is projected to witness growth at a CAGR of 32.8% during the forecast period with a market size of USD 170.10 million in 2024
• The Luxembourg Sitagliptin market is projected to witness growth at a CAGR of 33.8% during the forecast period, with a market size of USD 64.30 million in 2024.
• The Portugal Sitagliptin market is projected to witness growth at a CAGR of 33.5% during the forecast period, with a market size of USD 43.56 million in 2024.
• The Greece Sitagliptin market is projected to witness growth at a CAGR of 34.0% during the forecast period, with a market size of USD 24.89 million in 2024.
• The Rest of Europe's Sitagliptin market is projected to witness growth at a CAGR of 32.4% during the forecast period, with a market size of USD 321.52 million in 2024.

Asia Pacific Sitagliptin

According to Cognitive Market Research, the global Sitagliptin market size was estimated at USD 6914.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 1590.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 37.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Sitagliptin market size was valued at USD 715.65 million in 2024 and is projected to grow at a CAGR of 36.7% during the forecast period. China captures the largest share of the sitagliptin market due to its high diabetes prevalence and treatments.
• The Japan Sitagliptin market is projected to witness growth at a CAGR of 35.7% during the forecast period, with a market size of USD 219.47 million in 2024.
• The India Sitagliptin market had a market share of USD 190.84 million in 2024 and is projected to grow at a CAGR of 39.0% during the forecast period. India's sitagliptin market is experiencing rapid growth due to rising diabetes prevalence and enhanced treatment availability.
• The South Korean Sitagliptin market is projected to witness growth at a CAGR of 36.3% during the forecast period, with a market size of USD 159.03 million in 2024.
• The Australian Sitagliptin market is projected to witness growth at a CAGR of 36.9% during the forecast period, with a market size of USD 82.70 million in 2024.
• The Southeast Asia Sitagliptin market is projected to witness growth at a CAGR of 38.2% during the forecast period, with a market size of USD 109.73 million in 2024.
• The Rest of Asia Pacific Sitagliptin market is projected to witness growth at a CAGR of 37.0% during the forecast period, with a market size of USD 112.91 million in 2024.

South America Sitagliptin

According to Cognitive Market Research, the global Sitagliptin market size was estimated at USD 6914.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 345.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 34.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Sitagliptin market size was valued at USD 147.97 million in 2024 and is projected to grow at a CAGR of 35.2% during the forecast period. Brazil is ruling the sitagliptin market with its growing diabetic population and expanding healthcare access.
• Argentina's Sitagliptin market had a market share of USD 58.08 million in 2024 and is projected to grow at a CAGR of 35.5% during the forecast period. Argentina's growing demand for sitagliptin is fueled by the rising prevalence of diabetes and better treatment access.
• Colombia Sitagliptin market is projected to witness growth at a CAGR of 34.4% during the forecast period, with a market size of USD 30.77 million in 2024.
• Peru Sitagliptin market is projected to witness growth at a CAGR of 34.8% during the forecast period, with a market size of USD 28.35 million in 2024.
• The Chile Sitagliptin market is projected to witness growth at a CAGR of 34.9% during the forecast period, with a market size of USD 24.89 million in 2024.
• The Rest of Latin America's Sitagliptin market is projected to witness growth at a CAGR of 33.7% during the forecast period, with a market size of USD 55.66 million in 2024.

Middle East Sitagliptin

According to Cognitive Market Research, the global Sitagliptin market size was estimated at USD 6914.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 138.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 34.9% from 2024 to 2031..

• The GCC Countries Sitagliptin market is projected to witness growth at a CAGR of 35.7% during the forecast period, with a market size of USD 59.19 million in 2024. GCC Countries dominate the sitagliptin market due to advanced healthcare infrastructure and increasing diabetes management awareness.
• The Egypt Sitagliptin market is projected to witness growth at a CAGR of 35.2% during the forecast period, with a market size of USD 14.52 million in 2024.
• The South Africa Sitagliptin market is projected to witness growth at a CAGR of 35.9% during the forecast period, with a market size of USD 21.85 million in 2024. South Africa's sitagliptin market is experiencing flourishing sales due to rising diabetes cases and better treatment accessibility.
• The Turkey Sitagliptin market is projected to witness growth at a CAGR of 34.4% during the forecast period, with a market size of USD 11.89 million in 2024.
• The Nigeria Sitagliptin market is projected to witness growth at a CAGR of 34.0% during the forecast period, with a market size of USD 14.52 million in 2024.
• The Rest of the MEA Sitagliptin market is projected to witness growth at a CAGR of 33.9% during the forecast period, with a market size of USD 16.32 million in 2024.

Sitagliptin Market Analysis

How are Segments Performing in the Global Sitagliptin Market?

Sitagliptin Market Type Segment Analysis

According to Cognitive Market Research, tablets hold a major share in the sitagliptin market due to their convenience, ease of administration, and patient preference. Oral dosage forms are widely preferred for chronic conditions like diabetes as they offer better compliance compared to injectable forms. The availability of various tablet strengths and the ease of incorporating them into daily routines contribute to their dominance in the market for sitagliptin.

The injection form of sitagliptin is the fastest-growing segment in the market, as it offers an alternative for patients who have difficulty with oral medications. With an increasing preference for injectable diabetes treatments, especially among those with poor oral absorption or those requiring more precise control over blood glucose levels, this segment is gaining traction. Enhanced efficacy and convenience of injection-based therapies further contribute to its rapid growth.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Sitagliptin Industry. Request a Free Sample PDF!

Sitagliptin Market Application Segment Analysis

According to Cognitive Market Research, diabetes is expected to dominate the sitagliptin market due to the increasing global prevalence of the condition, especially type 2 diabetes. As the number of diagnosed cases continues to rise, the demand for effective oral treatments like sitagliptin increases. Improved awareness, advancements in diabetes management, and a shift toward more personalized healthcare also contribute to sitagliptin's growing presence in the global market for diabetes care.

The fastest growing segment of the sitagliptin market is the type 2 diabetes treatment sector. With the increasing prevalence of type 2 diabetes, the demand for effective oral medications like sitagliptin has surged. Factors such as an aging population, sedentary lifestyles, and rising obesity rates contribute to the growing number of diabetes cases, leading to higher adoption of sitagliptin as a preferred treatment option.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion